The efficacy of B7-1 (CD-86) transduced autologous tumor cell vaccine combined with IL-2 was evaluated in a single center phase II trial for the treatment of stage IV renal cell carcinoma (133). This evidence concerns the gene CD80 and hereditary clear cell renal cell carcinoma.